Stockreport

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Financial Post (Toronto, Ontario, Canada)]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced [Read more]